BioSpace News Archive

Cytocom, Inc., a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology, a not-for-profit academic institution and a world leader in immunology research.

ThermoGenesis Holdings, Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, reported financial and operating results for the second quarter ended June 30, 2021 and provided a corporate strategic update.

NovaBay® Pharmaceuticals, Inc. reports financial results for the three and six months ended June 30, 2021 and provides a business update.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2021 to all shareholders of record as of September 15, 2021.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced its second quarter 2021 financial results and corporate highlights.

Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, announced consolidated financial results for the three and nine months ended June 30, 2021.

Viveve Medical, Inc., a medical technology company focused on women’s intimate health, reported financial results for the quarter ended June 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

Dyadic International, Inc., a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for the second quarter of 2021 and highlighted recent Company progress.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its financial and operating results for the three and six months ended June 30, 2021 and provided a business update.

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, reported financial results for the second quarter ended June 30, 2021 and provided a business update.